{"slug":"tirzepatide-tirzepatide","verification":{"valid":true,"entries":2,"head":"dd73df5303353c012e21ad39973e66460255dc022307c15e9e0c323cb625ba25"},"energy":{"passes":2,"tokens_in":14390,"tokens_out":2952,"tokens_total":17342,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"dd73df5303353c012e21ad39973e66460255dc022307c15e9e0c323cb625ba25"},"provenance":[{"ts":"2026-06-29T22:37:57.922Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Tirzepatide\nSlug: tirzepatide-tirzepatide\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your conditio","response":"{\n  \"slug\": \"tirzepatide-tirzepatide\",\n  \"title\": \"Tirzepatide Evidence: Metabolic Load Reduction and Weight-Loss Pathways\",\n  \"body\": \"## What's breaking down\\n\\nHigher body weight creates sustained mechanical overload on the spine, joints, and supporting tissues. Each extra pound adds roughly four pounds of compressive force to the lumbar spine during standing or walking. Over time this shifts the balance toward degeneration: cartilage wear, disc compression, and chronic low-grade inflammation outpace natural repair processes. Tirzepatide is studied primarily as a dual GLP-1/GIP receptor agonist that promotes substantial weight reduction, thereby lowering that mechanical load rather than directly repairing tissue or masking symptoms.\\n\\n## Why Tirzepatide might help you\\n\\n1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tirzepatide addresses the metabolic load / body weight layer. If a broader profile includes additional degeneration layers, other agents would target those separately.\\n\\n## What the evidence actually shows\\n\\nHuman randomized controlled trials document large, dose-dependent weight reductions. In SURMOUNT-1, adults with obesity or overweight received tirzepatide 5 mg, 10 mg, or 15 mg once weekly for 72 weeks. Mean weight loss reached 15.0 %, 19.5 %, and 20.9 % respectively versus 3.1 % on placebo (human tier). SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide versus semaglutide over 72 weeks and found 20.2 % versus 13.7 % mean weight loss (human tier). SURMOUNT-4 showed that continued tirzepatide after initial loss maintained most o","tokens_in":14390,"tokens_out":2952,"cost":0,"prev":"genesis","hash":"8c68e1ad18d87c810974c7ccbefcff656bf70392f115e2608b622fc119a3c2a3"},{"ts":"2026-07-17T02:43:20.582Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-tirzepatide","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8c68e1ad18d87c810974c7ccbefcff656bf70392f115e2608b622fc119a3c2a3","hash":"dd73df5303353c012e21ad39973e66460255dc022307c15e9e0c323cb625ba25"}]}